Please login to the form below

Not currently logged in
Email:
Password:

Alnylam teams with Isis on joint startup

Alnylam forms jv company with Isis to commercialise microRNA-derived (miRN) drugs in the US

US-based Alnylam Pharmaceuticals has formed a joint venture (jv) company, Regulus Therapeutics, with Isis Pharmaceuticals to commercialise microRNA-derived (miRN) drugs in the US.

Regulus will combine technologies from Alnylam and Isis Pharmaceuticals to create the jv, which will be controlled by a separate management team, board of directors and scientific advisory board. The new firm will be chaired by Nobel prize winner, David Baltimore.

Alnylam added that the company will make an initial investment of USD 10m in Regulus, and will share future funding of the venture with Isis. Both Alnylam and Isis have granted the new company exclusive licenses to miRNA technology of Isis and Alnylam.

MiRN drugs are expected to be able to regulate multiple human genes with potential to treat a number of presently unmet medical needs.

Alnylam develops drugs which implement RNA-interference (RNAi) technology that works by switching off damaged or lethal genes thereby treating diseases. Alnylam reported a FY06 net loss of USD 34.6m on sales of USD 26.9m.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...